comprehensive -WSS

comprehensive

author：explore 2025-09-03 03:31:08 - browse：25

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： New oral drug delivery patch is modeled after octopus tentacles

hotspot

WSS

What will Novo Nordisk's VC do with its influx of cash?

Problems with a popular proposal to regulate AI in health care

AI gets buy

Adopting new red light myopia treatments may be short

The CDC's new social media misinformation war

Stop Congress from blocking public access to science

focus

comprehensive

focus

Bright Health sells Medicare Advantage business to Molina

Setback for rare diseases as Taysha Gene Therapies pulls back

Malaria cases in Florida and Texas: Here’s what you need to know

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Medical leaders decry Supreme Court decision on affirmative action

Unique patient identifier: Experts argue the benefits, pitfalls

Moonlake's readout produced a cash windfall. Risks remain

CDC picks Alphabet's Verily for wasterwater surveillance contract

Drug repurposing or repositioning? The language matters

The United States is paying nearly triple for new Covid vaccines

leisure time

Experts study whether long Covid risk adds up with each reinfection

The stability of $0 premiums in Medicare Advantage

Experts study whether long Covid risk adds up with each reinfection

AstraZeneca stays mum on Medicare drug pricing negotiations

WHO recommends second malaria vaccine

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

leisure time

Wikipedia

hotspot

leisure time